Takeda Pharmaceutical Company Limited Stock
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Japan Exchange
14:30:00 01/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 5,731.00 JPY | -0.85% |
|
-3.97% | +18.53% |
| 09-30 | Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading | MT |
| 09-30 | Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial | MT |
| Market Cap | 9,229B 58.73B 51.72B 49B 44.24B 83.37B 5,631B 84.45B 586B 226B 2,879B 221B 216B | P/E 2027 * |
45.8x | P/E 2028 * | 29.1x |
|---|---|---|---|---|---|
| Enterprise Value | 13,136B 83.59B 73.61B 69.74B 62.96B 119B 8,015B 120B 834B 321B 4,097B 314B 307B | EV / Sales 2027 * |
2.79x | EV / Sales 2028 * | 2.7x |
| Free-Float |
99.26% | Yield 2027 * |
3.54% | Yield 2028 * | 3.6% |
| Markets | Quality | ||
|---|---|---|---|
Japan Exchange
| 4502 | Delayed | |
Deutsche Boerse AG
| TKD | Delayed | |
|
OTC Markets
| TKPHF | Delayed | |
|
Börse Stuttgart
| TKD | Delayed | |
|
Tradegate
| TKD | Real-time | |
|
Boerse Muenchen
| TKD | Real-time | |
|
Wiener Boerse
| TKD | End-of-day quote |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | -0.85% | ||
| 1 week | -3.97% | ||
| Current month | -0.85% | ||
| 1 month | -0.59% | ||
| 3 months | +11.17% | ||
| 6 months | +1.18% | ||
| Current year | +18.53% |
| 1 week | 5,653 |  | 6,001 |
| 1 month | 5,557 | | 6,030 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 61 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 14/9/26 | Sell | Executive/Senior Manager | -34,535 | 0.0022% | ||
| 2/9/26 | Sell | Chief Technology Officer | -116,191 | 0.0073% | ||
| 19/8/26 | Sell | Chief Technology Officer | -19,651 | 0.0012% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.85% | -3.97% | +32.82% | +23.49% | 58.73B | |
| -0.43% | -2.99% | +38.91% | +113.00% | 1,031B | |
| -0.82% | -3.08% | +41.01% | +69.09% | 638B | |
| -0.54% | -2.11% | +6.20% | +75.07% | 462B | |
| -0.41% | -2.35% | +60.32% | +40.91% | 359B | |
| -0.33% | -4.46% | +22.99% | +39.97% | 335B | |
| -1.81% | -1.04% | +13.17% | +26.08% | 273B | |
| -1.92% | -3.03% | -3.31% | +9.81% | 253B | |
| -1.39% | +2.40% | +39.29% | +56.13% | 228B | |
| -0.84% | -1.37% | +32.83% | +99.25% | 185B | |
| Average | -0.93% | -0.64% | +28.42% | +55.28% | 382.26B | |
| Weighted average by Cap. | -0.76% | -0.39% | +30.92% | +69.45% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,704B 29.93B 26.36B 24.97B 22.54B 42.49B 2,870B 43.04B 299B 115B 1,467B 112B 110B | 4,794B 30.51B 26.86B 25.45B 22.98B 43.31B 2,925B 43.87B 305B 117B 1,495B 115B 112B |
| Net income | 196B 1.25B 1.1B 1.04B 942M 1.78B 120B 1.8B 12.48B 4.8B 61.29B 4.7B 4.59B | 323B 2.05B 1.81B 1.71B 1.55B 2.92B 197B 2.95B 20.5B 7.89B 101B 7.71B 7.54B |
| Net Debt | 3,907B 24.86B 21.89B 20.74B 18.72B 35.29B 2,383B 35.75B 248B 95.49B 1,218B 93.34B 91.31B | 3,702B 23.56B 20.75B 19.66B 17.74B 33.44B 2,259B 33.88B 235B 90.5B 1,155B 88.46B 86.53B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/10/26 | JP¥5,731.00 | -0.85% | 4,231,700 |
| 30/09/26 | JP¥5,780.00 | +0.71% | 5,243,000 |
| 29/09/26 | JP¥5,739.00 | -3.22% | 4,844,600 |
| 28/09/26 | JP¥5,930.00 | -0.65% | 4,933,900 |
| 25/09/26 | JP¥5,969.00 | +1.43% | 3,826,100 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
